Bimekizumab
Suicidal ideation, behavior rate low in psoriasis patients treated with bimekizumab
The long-term adjudicated suicidal ideation and behavior rate in patients with psoriasis treated with bimekizumab was low and within general psoriasis population ranges, according to a study.
VIDEO: Bimekizumab efficacious in severe psoriasis, may increase yeast infection risk
In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed study results presented at the American Academy of Dermatology Annual Meeting examining bimekizumab in the treatment of psoriasis.
New mechanisms, nanobody ‘revolution’ promising for psoriatic arthritis treatment
SCOTTSDALE, Ariz. — Interleukin-17 targeting, a tyrosine kinase 2 inhibitor and the “nanobody revolution” represent a promising new frontier for psoriatic arthritis, according to a speaker here.
VIDEO: Promising data for bimekizumab in psoriasis treatment
In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the recently approved interleukin-17 inhibitor bimekizumab from the Maui Derm 2024 meeting, examining its use in treating psoriasis.
Bimekizumab’s efficacy ‘favorable’ in psoriatic arthritis vs other approved treatments
Bimekizumab’s efficacy in psoriatic arthritis is “favorable” when compared with all other approved treatments in terms of both efficacy and safety, according to a systemic review and network meta-analysis published in Rheumatology.
Bimekizumab sustains effectiveness in psoriatic arthritis over 52 weeks
Bimekizumab remains effective after 52 weeks in patients with psoriatic arthritis, with no new safety concerns, according to data published in Annals of the Rheumatic Diseases.
Bimekizumab sustains axial spondyloarthritis improvements at 52 weeks
Patients with axial spondyloarthritis who receive bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, according to data published in the Annals of the Rheumatic Diseases.
FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis
The FDA has approved Bimzelx for moderate to severe plaque psoriasis treatment in adults who are eligible for systemic therapy or phototherapy, UCB announced in a press release.
Bimekizumab reduces disease severity among patients with hidradenitis suppurativa
New pooled results from the BE HEARD phase 3 trials show bimekizumab reduces disease severity in patients with moderate to severe hidradenitis suppurativa, according to a UCB press release.
EMA accepts marketing authorization for bimekizumab for hidradenitis suppurativa
The European Medicines Agency has accepted for review the marketing authorization application for bimekizumab for moderate to severe hidradenitis suppurativa treatment in adults, UCB announced in a press release.